Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.

Authors

null

Philippe E. Spiess

Moffitt Cancer Center, Tampa, FL

Philippe E. Spiess , Douglas A Mata , Gennady Bratslavsky , Joseph M Jacob , Andrea Necchi , Ole Gjoerup , Natalie Danziger , Douglas I. Lin , Brennan James Decker , Ethan Sokol , Richard Huang , Jeffrey S. Ross

Organizations

Moffitt Cancer Center, Tampa, FL, Foundation Medicine Inc., Cambridge, MA, SUNY Upstate University Hospital, Bethesda, MD, SUNY Upstate Medical University, Syracuse, NY, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Foundation Medicine, Cambridge, MA, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine, Inc, Morrisville, NC

Research Funding

Pharmaceutical/Biotech Company
Foundation Medicine Inc.

Background: Although SCC of the penile skin (pSCC) and the male urethral surface epithelium (uSCC) arise in nearby locations and can feature similar histology, their clinical manifestations, disease course, and surgical and medical treatment options are distinct. We performed CGP on pSCC and uSCC to examine genomic profiles differences. Methods: Tissues obtained from men with clinically advanced pSCC (n = 230) and uSCC (n = 17) underwent hybrid capture-based CGP to evaluate all classes of genomic alterations (GAs). Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA and microsatellite instability (MSI) was determined on up to 114 loci. PD-L1 expression was determined by IHC (Dako 22C3). Results: The median ages were similar in both groups. pSCC exhibited a slightly higher frequency of HPV-16/18 infection (29% vs. 12%, P = .16), although the TP53 mutation frequencies were nearly identical (55% vs. 59%, NS). CDKN2A inactivation (P = .08), CCND1 amplification trending higher and TERT promoter mutations (P = .01) were more frequent in pSCC, potentially indicating prior HPV infection. GAs in NOTCH1 were exclusively identified in pSCC. Potentially actionable GAs identified in both groups included PIK3CA activating mutations (TKIs) as well as pathogenic alterations in FBXW7 and PTEN (MTOR inhibitors). Rare BRCA1 and BRCA2 inactivation (PARP inhibitors) was seen in pSCC only. High-positive PD-L1 staining was elevated in pSCC (34 vs. 14%, P = .06). Although average TMB was similar in both groups, pSCC exhibited an elevated frequency of cases with CD274 (PD-L1) amplification as well as TMB >10 mut/Mb which are on label for immune checkpoint inhibitor (ICPI) treatment. Conclusions: CGP of pSCC and uSCC identifies opportunities for both targeted and ICPI therapies. Compared to uSCC, pSCC had genomic features more similar to head and neck SCC including slightly increased cell-cycle perturbation, HPV infection, and NOTCH pathway signaling alterations. Further use of CGP in the treatment planning for pSCC and uSCC may be warranted.

Penile SCC
(n = 230)
Male Urethral SCC
(n = 17)
Significance
Median age (range), years65 (24-92)63 (40-76)NS
GAs/tumor5.74.9NS
HPV-6/113%0%NS
HPV-16/1829%12%NS
BRCA1< 1%0%NS
BRCA23%0%NS
CCND1 amplification15%6%NS
CD274 amplification6%0%NS
CDKN2A inactivation47%24%P = 0.08
CDKN2B inactivation9%0%NS
EGFR amplification14%12%NS
FBXW78%6%NS
FGFR33%6%NS
NOTCH117%0%P = 0.08
PIK3CA22%30%NS
PTEN inactivation4%6%NS
TERT promoter mutation44%13%P = 0.01
TP5355%59%NS
MSI High1%0%NS
Median TMB3.83.8NS
Mean TMB5.76.5NS
TMB >10 mt/Mb15%6%NS
TMB >20 mt/Mb5%6%NS
PD-L1 Low Positive (1-49%)25%28%NS
PD-L1 High Positive (≥50%)34%14%P = 0.06

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

General Session

Session Title

Evolving Management of Locally Advanced Penile Cancer

Track

Penile, Urethral, Testicular, and Adrenal Cancers

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 2)

DOI

10.1200/JCO.2021.39.6_suppl.2

Abstract #

2

Abstract Disclosures

Similar Abstracts

First Author: Rebecca A Sager

Abstract

2022 ASCO Genitourinary Cancers Symposium

Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.

First Author: Petros Grivas

First Author: Stephanie Lakritz

First Author: Philippe E. Spiess